Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20064043 | 0.98 | TSHR (0.52) | L3MBTL1TSHRALDH1A1LMNAKDM4E | |
| SCHEMBL25694634 | 0.86 | TSHR (0.56) | L3MBTL1TSHRALDH1A1LMNAKDM4E | |
| SCHEMBL11310489 | 0.86 | TSHR (0.56) | L3MBTL1TSHRALDH1A1LMNAKDM4E | |
| Hydrochloric Acid SCHEMBL4740477 | 0.86 | SLC1A1 (0.49) | L3MBTL1TSHRALDH1A1LMNAKDM4E | |
| Hydrochloric Acid SCHEMBL8144696 | 0.86 | ALDH1A1 (0.54) | L3MBTL1TSHRALDH1A1LMNAPPARG | |
| Hydrochloric Acid SCHEMBL26626701 | 0.86 | ALDH1A1 (0.54) | L3MBTL1TSHRALDH1A1LMNAPPARG | |
| SCHEMBL2948709 | 0.84 | TSHR (0.50) | L3MBTL1TSHRALDH1A1LMNAKDM4E | |
| SCHEMBL8586587 | 0.84 | ALDH1A1 (0.56) | L3MBTL1TSHRALDH1A1LMNAPPARG | |
| SCHEMBL8584594 | 0.84 | ALDH1A1 (0.56) | L3MBTL1TSHRALDH1A1LMNAPPARG | |
| SCHEMBL5306511 | 0.84 | ALDH1A1 (0.56) | L3MBTL1TSHRALDH1A1LMNAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105572-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2011-05-05 | — | — | US | disclosed |
| US-7880020-B2 | e.g trichlorostatin A; antiproliferative agent; for treating cancer and psoriasis | TOPOTARGET UK LIMITED (GB) | 2011-02-01 | — | — | US | disclosed |
| US-20100249197-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2010-09-30 | — | — | US | disclosed |
| US-7569724-B2 | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
| EP-2083005-A1 | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors | TopoTarget UK Limited (GB) | 2009-07-29 | — | — | EP | disclosed |
| EP-1598067-B1 | Carbamic acid compounds comprising an amide linkage for the treatment of malaria | TOPOTARGET UK LTD (GB) | 2009-05-06 | — | — | EP | disclosed |
| EP-1335898-B1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LTD (GB) | 2005-11-23 | — | — | EP | disclosed |
| EP-1598067-A1 | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors | TopoTarget UK Limited (GB) | 2005-11-23 | — | — | EP | disclosed |
| US-20040092598-A1 | Carbamic acid compounds comprising an amide linkage as hdac inhibitors | TOPOTARGET UK LIMITED (GB) | 2004-05-13 | — | — | US | disclosed |
| EP-1335898-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | Prolifix Limited (GB) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002026696-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | PROLIFIX LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
| US-5650428-A | THROMBOXANE A2 ANTAGONISM | NKK CORPORATION (JP) | 1997-07-22 | — | — | US | disclosed |
| CN-1111453-A | Aryl sulfonamide derivatives and pharmaceutical compositions containing the same | NIPPON KOKAN KK (JP) | 1995-11-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092598-A1 | Carbamic acid compounds comprising an amide linkage as hdac inhibitors | HDAC1, HDAC11, HDAC3 | PPARG 73/4885L3MBTL1 1468/4885TSHR 2954/4885 |
| US-20110105572-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | HDAC1, HDAC7, HDAC5 | PPARG 339/4885L3MBTL1 1697/4885TSHR 2210/4885 |
| US-20100249197-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | HDAC1, HDAC11, HDAC3 | PPARG 66/4885L3MBTL1 2386/4885TSHR 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.